Long-Term Outcomes of Drug-Refractory Atrial Fibrillation After Atrioventricular Node Ablation Combined with

Bagdat A Akhyt1, Salim F Berkinbaev2, Natalya G Lozhkina3,4

  • 1JSC "Research Institute of Cardiology and Internal Medicine", Almaty 050000, Kazakhstan.

PubMed

Insights

This study identified key predictors of 5-year mortality in patients with drug-refractory atrial fibrillation treated with atrioventricular node ablation and CRT-D. Machine learning identified factors like ejection fraction and pulmonary artery pressure for risk stratification.

Area of Science:

  • Cardiology
  • Medical Technology

Background:

  • Drug-refractory tachysystolic atrial fibrillation poses significant mortality risks.
  • Atrioventricular node ablation (AVNA) combined with CRT-D is a treatment option for these patients.

Purpose of the Study:

  • To identify significant risk factors for 5-year mortality in patients undergoing AVNA and CRT-D.
  • To explore the predictive accuracy of machine learning models for mortality outcomes.

Main Methods:

  • Prospective single-center cohort study of 101 patients with chronic heart failure and drug-refractory atrial fibrillation.
  • Patients underwent AVNA and CRT-D implantation, receiving optimal medical therapy.
  • Machine learning methods (random forest, Shapley additive explanations) were used to assess mortality predictors.

Main Results:

  • 13 cardiovascular deaths occurred during 5-year follow-up.
  • Key mortality predictors identified: left ventricular ejection fraction, 6 min walk distance, mean pulmonary artery pressure, systolic relaxation coefficient, and mitral regurgitation.
  • The predictive model achieved 92% accuracy in outcome classification.

Conclusions:

  • AVNA combined with CRT-D is associated with long-term clinical outcomes in this patient group.
  • Machine learning analysis successfully identified key mortality-associated factors.
  • These findings can aid in personalized risk stratification and hypothesis generation for atrial fibrillation management.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
310
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
431
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
233
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
366
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
385
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
2.4K